MyBlueDots

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. Preliminary Full Year 2024 Revenue Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company’s previous full year guidance range of $83.0
Read More

Commonwealth Care Alliance® Recognized as Leader in LGBTQ+ Workplace Inclusion

BOSTON–(BUSINESS WIRE)–Commonwealth Care Alliance® (CCA), a mission-driven healthcare services organization that offers high-quality health plans and care delivery programs designed for individuals with the most significant needs, today announced that it has been recognized as a 2025 “Leader in LGBTQ+ Workplace Inclusion” by the Human Rights Campaign Foundation, earning a perfect score of 100% on their Corporate Equality Index (CEI). The Human Rights Campaign Foundation’s CEI is the premier n
Read More

Viz.ai Secures New Partnerships with Three Global Pharmaceutical Companies as Growth in Hospital Footprint Expands to 60,000 Providers

SAN FRANCISCO–(BUSINESS WIRE)– #aihealthcare–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced significant milestones in its mission to transform healthcare delivery. In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai expanded its reach to serve 1,700 hospitals with a broad user base that grew by more than 30%
Read More

Validic Advances Personalized Patient Care by Integrating Wearable Data in EHR Workflow

LAS VEGAS–(BUSINESS WIRE)– #applewatch–CES–Validic, a leader in digital health and personalized care technology, today announced the integration of physical activity data from wearables and smartwatches into electronic health record (EHR) clinical workflows. This multi-device solution, available in Epic and Oracle Health EHR systems, adds daily insights from more than 350 wearable device models from leading consumer brands, including Apple, Fitbit, Garmin, Google, Oura, Samsung, and Withings to the patie
Read More

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

BURLINGTON, Mass.–(BUSINESS WIRE)–Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions. The updated release reads: PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FROM SURPASS-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT (P1101) FOR ESSENTIAL THROMBOCYTHEMIA SURPASS-ET trial achieved its primary endpoint, demonstrating a durable response in 42.9% of participants in the P1101 group versus 6.0% in the comparator group (p=0.0
Read More

Dr. Timothy A. Schaub Joins Luskin Orthopaedic Institute for Children as Head of Hand and Microsurgery Center

LOS ANGELES–(BUSINESS WIRE)– #HolidayGiving–The Luskin Orthopaedic Institute for Children (LuskinOIC) proudly announces the appointment of Dr. Timothy A. Schaub, M.D., F.A.C.S., MBA as the Head of the Hand and Microsurgery Center. With a distinguished career spanning decades and a reputation for innovative approaches in pediatric hand and microsurgical care, Dr. Schaub brings unparalleled expertise to LuskinOIC’s mission of providing world-class, compassionate care to children. Dr. Schaub joined LuskinOIC in
Read More

Grove Secures $4.9 Million to Transform Clinical Trials with Agentic AI

SAN FRANCISCO–(BUSINESS WIRE)–Grove AI, a next-generation clinical trial management and intelligence company, today announced a $4.9 million seed fundraise led by A*, with participation from Afore Capital, LifeX Ventures, Pear VC, Upfront Ventures, and industry-leading angels. This investment will allow Grove to continue scaling its team and product to redefine clinical trials from siloed operations into participant-centered ecosystems driven by real-time data. Despite their vital role in adv
Read More
Top